Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
SBP GROUP's Subsidiary Presents Research Data on 2 Self-Developed ADCs at AACR Annual Meeting
Recommend 16 Positive 27 Negative 9 |
||||
|
||||
|
SBP GROUP (01177.HK) announced that the latest research data of LM-364 "Nectin-4TME ADC" and LM-338 "STn ADC", two antibody-drug conjugates (ADCs) independently developed by LaNova Medicines, its wholly-owned subsidiary, has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. Specifically, LM-364 is a next-generation Nectin-4TME ADC developed by LaNova Medicines leveraging its proprietary tumor microenvironment (TME) platform. This molecule employs an adenine nucleotide (ANP)-dependent binding mechanism: since ANP concentration in the tumor microenvironment (micromolar level) is significantly higher than that in normal tissues (nanomolar level), LM-364 achieves conditionally activated high-affinity binding at tumor sites. This enhances internalization and payload release while significantly reducing off-target toxicity in normal tissues, offering a novel approach to addressing long-standing safety challenges in ADC development. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
